Idemitsu Kosan Co.,Ltd. (TSE:5019) entered into Share Exchange Agreement to acquire remaining 30.3% stake in SDS Biotech K.K. (TSE:4952) from group of sellers for ¥3.1 billion on May 11, 2021. As per terms of transaction, Idemitsu Kosan Co.,Ltd. will pay ¥1440 for each share. Post completion, SDS Biotech K.K. will become wholly owned subsidiary of Idemitsu Kosan Co.,Ltd. SDS Biotech Stock will be delisted as of July 29, 2021. The transaction is subject to shareholder approval of SDS Biotech K.K. On June 23, 2021, the Ordinary General Meeting of shareholders of SDS Biotech K.K. approved the transaction. The transaction is expected to complete on August 2, 2021. Nomura Securities Co., Ltd. acted as financial advisor and Ryutaro Nakayama, Yuki Oi, Takeshi Nemoto and Kazumaro Kobayashi of Nishimura & Asahi acted as legal advisors to Idemitsu Kosan Co.,Ltd. Mizuho Securities Co., Ltd. acted as financial advisor and TMI Associates acted as legal advisor to SDS Biotech K.K.

Idemitsu Kosan Co.,Ltd. (TSE:5019) completed the acquisition of remaining 30.3% stake in SDS Biotech K.K. (TSE:4952) from group of sellers on July 28, 2021.